posit weak quarter
quest clearli deliv top-lin result expect share
vs today new issu present
first time said believ overweight thesi around
share gain continu hold see favor risk/reward profil
invest main focu earn equival revenu growth
came lighter forecast result surpris us
market given lab oper histor stabl year
quest attribut miss three factor think could improv
throughout remaind specif quest highlight payor chang
prescript drug monitor vitamin test well greater expect
declin hepat genotyp quantifi call believ
factor headwind quarter exemplifi
deceler revenu growth q/q despit easier comp weather/calendar
look forward believ progress revers prescript drug monitor
decis could re-acceler volum growth quest note alreadi
success one payor around revers decis prescript drug monitor
made progress sever other quest also note dialogu
hospit system remain activ around outsourc lab oper
quiet view time relat activ believ
activ could acceler final believ opportun ahead
quest compani new contract help break
barrier nation lab consolid share test improv
patient experi payor new relationship major shift
opinion payor put place new tool encourag physician
steer patient toward prefer network high qualiti laboratori deliv good
valu describ observ number get larg quickli
current valuat believ investor free call option potenti
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
return equiti ttm
link barclay live interact chart
overweight believ quest long
runway deliv strategi acceler growth
deliv oper excel point new
payor relationship help drive lab test share
toward nation lab time addit
believ quest meaning leverag
diagnost data asset custom
upsid case assum quest aggreg
increment test share drive upsid
case ep earn begin
acceler believ multipl room
expans well given long runway
downsid case assum softer util
well increment wage pressur busi
cost repres downsid
case ep
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
quest clearli deliv top-lin result expect share
vs today new issu present
first time said believ overweight thesi around share gain
continu hold see favor risk/reward profil invest
main focu earn equival revenu growth came
lighter forecast result surpris us market given lab
oper histor stabl year quest attribut miss three
factor think could improv throughout remaind specif
quest highlight payor chang prescript drug monitor vitamin test
well greater expect declin hepat genotyp relat launch
abbvi new therapeut quantifi call believ factor
headwind quarter exemplifi deceler revenu
growth q/q despit easier comp weather/calendar
look forward believ progress revers prescript drug monitor
decis could re-acceler volum growth quest note alreadi success
one payor around revers decis prescript drug monitor
made progress sever other quest also note dialogu hospit
system remain activ around outsourc lab oper quiet
view time relat activ believ activ could acceler
final believ opportun ahead quest
compani new contract help break barrier
nation lab consolid share test improv patient experi
payor new relationship major shift opinion payor
put place new tool encourag physician steer patient toward prefer
network high qualiti laboratori deliv good valu describ observ
number get larg quickli current valuat believ investor
free call option potenti consolid upsid
continu believ quest favor risk/reward profil
valuat methodolog take weight averag potenti scenario partial
account lab consolid opportun new payor paradigm
believ investor good visibl result least achiev
base case scenario forecast ep repres growth y/i
squar middl quest long-term guidanc mid-to-high singl digit
earn growth increas prior forecast quest
sever compel opportun augment growth new aetna
payor renew net posit quest base case forecast modest
contribut consolid barrier entri break nation lab
addit encourag quest effort leverag diagnost data asset
drive valu health system custom util trend remain stabl driven
grow popul age demograph well push toward
person medicin importantli pama embed forecast
believ worth own share given potenti leverag upsid
lab consolid driven new payor paradigm upsid case
assum quest aggreg increment test share drive upsid
ep forecast benchmark keep mind quest labcorp
collect aggreg share earn acceler believ
multipl room expans well given long runway potenti
consolid likelihood year number also trend higher growth
frankli dont believ signific downsid point worst case
scenario pama number model cut
addit recent renew nation payor contract improv visibl
long-term relationship chang contract paradigm way favor
nation lab valu proposit downsid case assum softer
util well increment wage pressur busi cost see
limit probabl downsid point given new payor contract improv
near-term rate visibl lead increment volum opportun
oper effici quest signific runway continu pull cost
busi autom procur lab footprint consolid
price repres blend blend ep scenario analysi
yield multipl ep forecast
price base weight averag scenario analysi
quest narrow guidanc given softer expect
think import compani execut new busi arrang
hospit hit target quest expect adjust revenu billion
top end billion repres equival growth y/i embed
equival growth growth acquisit close also includ
impact implement move bad debt expens
expens line within sg becom contra-revenu item quest guid adj
tax rate vs million expect tax save quest plan
reinvest approxim million million paid employe
form bonus addit quest expect gener cffo deploy
capital-expenditure emb unannounc capit deploy estim
adj ep expect rang includ
net benefit tax reform benefit re-invest ep
ex-tax reform impli growth y/i midpoint exclud
incom tax benefit quest guidanc assum ep
headwind unit price includ pama within unit price pressur
impli pama headwind million pre-tax cut given medicar
clf exposur million consist quest previou commentari follow
epsmultipleoutcomerel pricenotesbas lab share revenue upsid epsdownsid volum wage pressur barclay quest diagnost
quest report billion revenu quarter repres equival
growth y/i inc came meaning forecast
compani attribut three test area post unexpectedli softer result
revenu laboratori test increas revenu decreas
y/i volum increas y/i weaker estim adjust
acquisit estim shiel peacehealth medfusion/clearpoint etc
net new pl busi estim peacehealth estim underli
util increas y/i weaker recent trend revenu per requisit
increas y/i weaker q/q lower forecast keep
mind price expect remain modest impact pama combin
new hospit busi drive revenu per requisit lower believ underli
trend around stabl price unit cost improv mix gene-bas
esoter test remain unchang
specif quest note prescript drug monitor hepat genotyp
vitamin area pressur quarter collect believ could
impact quarter given magnitud miss
prescript drug monitor quest note payor implement polici
chang limit growth test quest engag payor show
medic necess test note far success get least one
payor revers cours addit success would reduc headwind
would creat easier comp quest note well road
discuss coupl payor made chang optimist
view medic appropri approach necessari
import area test plan place count
one payor revers coupl other feel like make
progress space
hepat genotyp quest said saw faster expect declin
genotyp resist test attribut new hepat
therapi work across multipl gene requir test quest
assum headwind test though impact wors
expect think unlik headwind moder
vitamin test quest note volum slow quarter due increas
reimburs denial quest note work payor provid
ensur appropri test perform patient need includ
patient comorbid condit specif quest note realli market
probabl alway code appropri chang vitamin
make lot peopl elig test practic peopl
still use old code understand go impact
provid think increas educ around appropri vitamin
test cours support ensur code accur
well ensur provid get paid
quarterli revenu million organ growth
underli driver revenu growth quest
revenueorgan growth y/i assumptionstot growth equival trial total test y/i lab organ total requisit y/i y/i organ net new weather calendar underli ppa per y/i y/i organ rev medicar pama overal y/i organ growth barclay quest diagnost
pleas see report
risk/reward new payor
paradigm upgrad ow
believ opportun ahead quest compani new
contract help break barrier nation lab
consolid share test improv patient experi payor
remind quest labcorp announc new contract may
view game-chang industri previous quest labcorp
exclus relationship aetna respect
open januari new relationship major shift
opinion payor put place new tool encourag physician steer
patient toward prefer network high qualiti laboratori deliv good
valu could provid detail potenti new benefit design sometim later
summer/earli fall order market plan year though time
ultim hand dont want rule time could get delay
well quest provid framework benefit design could look like
includ prefer network laboratori base valu proposit includ
time etc capabl around price transpar tool real-tim auto
adjud given differenti invest quest labcorp put
consum tool real-tim auto adjud vs region peer two nation
lab would obviou beneficiari prefer network implement
think could big deal share save prefer lab
volum shift high-cost set first lab industri volum
shift high-cost provid toward prefer network plan
develop pool save share provid instead
commodit lab lab result qualiti metric differenti
particip price tool incentiv effici deliveri care encourag
util prefer network also consid put place
econom incent patient physician adher network would
also first histori lab industri would includ waiv out-of-pocket
cost patient co-pay deduct encourag adopt given
rapid growth high-deduct health plan past decad believ could
drive strong incent patient better direct shift volum
discuss next continu think share dynam labcorp quest vs
rest industri far materi relev share dynam
two nation lab said obvious share shift
quest labcorp aetna contract open
believ net yield modest benefit quest modest
headwind labcorp simpl math larger aetna would
suggest quest net beneficiari vice versa labcorp said fact
labcorp earn price increas critic element
deal calculu also cement truli paradigm shift industri
base case analysi assum around ebitda tailwind quest
around ebitda headwind labcorp
rate quest note think got fair price good
market valu move out-of-network provid in-
network statu actual creat price headwind quest also great job
exemplifi lab industri issu first place analysi peg
discount visibl low statist less relev full
analysi given small current size revenu payor importantli
note labcorp messag compani receiv price increas
larger size revenu believ modest peg
volum quest expect substanti gain
compani quest note dynam differ time around network
open lab analysi assum base case volum
shift labcorp quest though imposs quantifi point
would increas quest share revenu estim
pro forma
similarli aetna quest expect cede volum back labcorp back in-
network assum percentag volum shift equival volum shift
though also imposs quantifi point also assum
similar price dynam new contract would increas
labcorp share revenu aetna estim pro forma
base case estim potenti price/mix chang labcorp contract mm
clearli much bigger opportun quest labcorp test consolid
lab across payor repres industri look back
past decad obviou nobodi origin nation exclus
contract nation lab nation payor patient quest note
nation payor recogn need work nation lab better drive
payor enu shift mmlabcorpquesttot labstot totalunitedhealth chang chang aet aet shift mmlabcorpquesttot labstot totaltot aet chang payor payor compani impact mmlabcorpquesttot ebitda compani ebitda barclay quest diagnost
valu system old contract allow region lab better penetr physician
offic could arbitrag benefit fact nation lab out-
of-network one nation payor drove higher price nation payor
overal higher out-of-pocket cost patient quest believ old payor
paradigm drove complex physician would field question
patient around unexpect lab cost back in-network remov unnecessari
barrier compet nation lab quest note earn
new volum earn volum across payer quest
look flip physician offic quest earn full book busi
compani start low-hang fruit quest domin physician offic
except volum alon quest ear-mark invest
make sure enough phlebotomist courier handl increas demand well
commit salesforc incent drive home addit volum quest
salesforc individu span geograph territori across countri
quest think share could move quickli commerci execut
get messag obviou headwind account prefer
peer quest equal need defend turf number get larg quickli
current valuat believ investor free call option potenti
consolid upsid outsid hospit lab opportun size around
billion nation lab repres share everi market share
assum meaning price discount quest fee schedul yield million
addit revenu quest growth quest estim increment margin
would impli earn growth almost pull-through believ
best outcom investor lab industri consolid organ
payor drive share nation lab hand without need cash outlay
outsid hospit opportun
increment ep increment share gain
consolid test major theme coverag past year
believ see earli signal result acceler quest
labcorp quest post lab growth includ organ
acquir growth quest best growth sinc labcorp post
total lab growth includ organ acquir growth
labcorp best growth sinc sinc averag revenu growth
lab highlight recent acceler growth consolid
increment revenu growthincrement share pieincrement quest rev mminc marginpric discount quest fee schedul barclay quest diagnost
total revenu growth lab busi
organ revenu growth lab busi
quest activ new acquisit partnership divestitur
continu impact pace growth continu believ
effort provid better healthcar integr patient cost share greater
regul fda ldt reimburs pressur pama driver share
consolid toward effici provid quest labcorp organ
growth modest compani done effect job win new busi
hospit partnership acquisit compani spent million
ytd million full year
us market continu fragment share repres
two independ market leader confer call ceo steve rusckowski
note first element growth strategi grow strateg
align accret acquisit achiev fifth consecut year
product quarter complet acquisit medxm lead
nation provid home-bas health risk assess relat servic
acquisit minut integr acquisit announc latter half
pleas result guid earlier year expect
affili lab barclay quest diagnost
deliv basi point growth top end
object pipelin remain strong strategi deliv
believ reimburs pressur drive lab consolid smaller competitor
lack scale drive effici busi margin come increas
pressur labcorp kick deal activ acquisit mt sinai outreach
oper follow sizabl paml acquisit ad million refer
lab test busi affili provid system cathol
initi quest similarli activ deal manag montefior inpati
routin test follow acquisition/partnership peacehealth
million acquisit medfusion/clearpoint texa addit late
year compani complet four addit outreach acquisit includ cape cod
healthcar cchc shiel medic laboratori hartford healthcar cla quest also
struck inpatient/outpati arrang cleveland heartlab octob
final sonic gotten action two jv nyu nyc
connecticut health network deal activ eclips million lab industri
revenu aggreg us industri revenu look chart
clear pace partnership acquisit pick
 clinic laboratori acquisit partnership
believ uptick laboratori deal activ partial attribut pama
uncertainti major driver thesi industri remind
updat reimburs laboratori test went effect januari
clearli mind industri particip hospit laboratori view non-cor
part health system ideal area hospit gener save strike
deal labcorp quest allow hospit focu core busi
continu provid patient access qualiti laboratori servic mani hospit
system alreadi financi pressur pama repres increment risk
drive manag team chang decision-mak
quest announc seven partnerships/d mark acceler rel
recent year compani expect growth deal provid larger impact
state guidanc transact improv visibl top line growth
help off-set price headwind pama quest organ hospit
relationship two strategi
yeardealslabtarget/partnerdatetyp sinai region laboratori associ outreach clinic outreach medic laboratori jvquestcap cod care outreach acquisitionquestm fusion associ medic laboratori laboratori outreach acquisit servicessonicwestern connecticut network venturequestmontefior serviceslabcorpmount acquisitionlabcorpclearpath lab lab acquisitionquesthca serviceslabcorphenri mayo newel acquisitionquestclin laboratori partner hartford outreach acquisit barclay quest diagnost
profession lab servic pl quest work hospit offer lab manag
servic within hospit inpati outpati procedur area save
includ refer work integr quest test network procur save
quest purchas scale employe manag product improv
contract negoti hospit way allow hospit save
money quest make margin inpati outpati test
servic typic bundl part drg code given procedur reimburs
medicar part ipp opp respect hospit
unwil part lab ownership give quest opportun
gener instant save reson new relationship notabl
shown chart quest announc pl arrang barnaba
new jersey hca one hospit network denver montefior
outreach acquisit absent integr deal quest activ
acquisit hospit outreach test hospit outreach compet directli
two nation lab busi gener physician offic altern site
follow acquisit hospit lab revenu get reset lower onto labcorp
quest fee schedul major payor sizabl reduct
greater despit rate reset nation lab believ abl drive
signific effici still achiev ebitda margin mid-teen
pleas see report
quest continu believ pama creat meaning headwind medicar
reimburs next sever year remind implement pama
kick largest chang diagnost reimburs year
result confirm belief pama lead meaning medicar cut time
lead period heighten lab industri consolid call quest confirm
pama impact expect serv headwind compani
medicar revenu financi impact still
meaning yet manag given medicar clf repres quest
revenu assum drop-through price reduct equat
counterpartydatetypedescriptionquestcalifornia laboratori associ outreach acquisitionquest acquir cla outreach laboratori support provid saint joseph lo angel area cleveland clinic servicesspeci test identif heart diseas hartford outreach acquisitionquest acquir outreach oper central ct backu hospitalsshiel medic laboratori acquisitionacquir shiel freseniu medic shiel lab new york new jersey close volum flow quest region lab teterboro nj cape cod care outreach acquisitionquest respons test previous perform cchc freestand center core lab test consolid quest marlborough laboratori med fusion lab associ us oncolog network prefer provid inpatient/outpati dx servic baylor scott white outreach acquisit inpatient/outpati servicesquest acquir peac hospit outreach busi addit quest manag inpati outpati laboratori peac medic center peac retain ownership laboratori employe remain part hospit montefior servicesquest partner montefior oper portion low complex diagnost test teterboro nj lab remaind test remain hous servicesquest manag inpati laboratori oper six one hospit denver co clinic laboratori partner hartford outreach acquisitionquest acquir laboratori outreach busi clinic laboratori partner inpati outpati busi remain part hartford system barnaba servicesquest manag barnaba inpati outpati laboratori servic within hospit system memori outreach acquisitionlaboratori outreach laboratori test shift quest facil west hill ca memori system hospital-bas laboratori part transact steward outreach acquisitionquest provid outreach laboratori servic physician nurs home provid previous servic steward umass memori outreach acquisitionlaboratori outreach laboratori test shift quest facil new facil marlborough barclay quest diagnost
ep headwind around medicar reimburs chang
actual sizabl survey work interact lab director suggest
industri experi period meaning consolid ultim believ smaller
lab outsiz medicar exposur consolid time either organ
inorgan benefit labcorp quest industri leader
earn call manag provid updat pama ceo steve
rusckowski note continu support effort trade associ implement
market-bas laboratori reimburs schedul legal front acla su
side submit brief court await judg rule
brief set date hear oral argument meantim continu
outreach effort find legisl solut earlier month pleas learn
ask stakehold provid comment improv futur data
collect report period pama proper step sinc said
along pama current report requir undermin effort establish
sustain market-bas payment model deliv care patient need
continu expect pama remain headwind forecast
quot headlin medicar cut clf time roughli
code see rate decreas vs rate increas code
rate reduct greater labcorp quest estim around
top code see rate reduct annual first year reduct
increasingli sever routin test estim top
hcpc code clf spend cut altogeth top code
contribut clf spend almost million claim
design top code gener billion clf payment
top code cut genom health oncotyp dx top code
increas top code cut impli
medicar reimburs payment still weight median
averag addit anoth three test cut display magnitud
futur cut top code includ lipid panel reduct
code contribut nearli clf spend code drug
test def class new volum weight median pama reduct
overal continu believ signific rate reduct routin code
lead increas outsourc effici provid labcorp quest
top hcpc code clf spend
pleas see report
takeaway clfs/pama
propos
potenti off-set horizon propos physician
fee schedul announc seek public comment definit chang
applic lab could broaden scope lab survey next pama data
reimburs depend number addit hospit outreach lab
survey report period clear chang view
expect medicar rate cut pama rate lock
data report period remind data report take place everi
year said think market may view posit given potenti
rate increas relief futur cut current model addit cut
histor defin applic lab base lab nation provid identifi
npi whether medicar revenu gener npi
clf hospit lab npi sit parent hospit level given
hospit gener major revenu ipp opp fee schedul vs
clf npi applic lab definit exclud mani hospit lab data
collect period vast major data submit pama data
collect period labcorp quest seek comment
whether use file bill type clia certif number
would recommend read brief section page propos
describ merit drawback use clia certif number
agenc chose use past lab industri histor lobbi
use clia number would put focu back lab report entiti
possibl major hospit lab medicar revenu clf
caveat clia number may repres entir hospit lab rather
outreach lab ipps/opp payment may larger clf revenu
hcpc codehcpc code descriptiontot claim linestot payment total nlaweight median payment w/ payment w/ payment w/ thyroid stim metabol cbc w/auto diff hemoglobin test def panel total test def parathormon psa free culture/coloni test def test def natriuret colorect breast cbc folic acid suscept barclay quest diagnost
broader inclus hospit outreach lab could lead increas medicar
reimburs base volum weight median rate submiss
labcorp quest undoubtedli still domin data collect period
inclus higher cost lab could lift higher wherev volum weight median lie
make adjust weather calendar impact acquisit new
busi underli util appear weaken due
headwind quest cite overal volum grew quarter emb
contribut acquisit fusion/clearpoint peacehealth etc
estim contribut peacehealth pl arrang follow
adjust estim underli util y/i
q/q quest continu encourag esoter genom test volum
compani also call prescript drug monitor quantiferon-tb driver
growth said new headwind quarter led shortfal rel
note organ volum growth adjust
quest result actual
note organ adjust volum growth adjust weather notabl net new busi calendar
quest result actual
revenu per requisit compris unit price variat busi mix test mix
underli price trend determin unit price less
quarter pama headwind
line prior
expect test payer mix serv tailwind revenu per requisit quest
ad acquisit meaning rev-per-req quarter
rev-per-req
note organ reimburs growth adjust fx beacon lb labcorp adjust mix
quest result actual
sg ex- stock comp expect sg
percentag net revenu y/i q/q due
revenu report net bad debt adjust margin calcul
compar given bad debt net revenu charg
longer report oper expens item
sg trend revenu
adjust ebit decreas y/i million came
estim million oper margin base net revenu
declin y/i line forecast encourag
compani show disciplin cost control quarter lower expect
revenu maintain overal earn compani
adj margin trend revenu
cffo posit million repres adjust net incom
quarter capital-expenditure million repres revenu final quest deploy
million dividend sharehold toward
quest
repurchas share quarter attribut black period relat
new contract announc
quest continu gener signific free cash flow priorit toward
return sharehold estim compani exit net debt
ttm ebitda par histor level compani expect cffo
billion capital-expenditure rang million impli rang
use oper million
 mm except ep reportedincom growth ebitda ebit pre-tax tax net adj net researchprior yearprior quarter barclay
meehan cfa herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
